Nodofree (Dorzolamide Hydrochloride)

Dorzolamide, the active ingredient in Nodofree, is a carbonic anhydrase inhibitor presented as an ophthalmic preparation for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma and ocular hypertension. GNH USA supplies Nodofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dorzolamide acts on the aqueous humor production pathway to control eye pressure in glaucoma‑related conditions. Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent development of glaucoma. Secondary glaucoma (e.g., pigmentary or pseudoexfoliative): helps control pressure when other agents are insufficient.

Common Side Effects: - Burning or stinging sensation in the eye. - Transient blurred vision after instillation. - Altered taste sensation. - Dry eye or foreign‑body feeling. - Conjunctival hyperemia. - Mild eye irritation.

Serious or Rare Side Effects: - Allergic reactions such as angioedema or severe eye swelling. - Persistent or worsening blurred vision. - Corneal edema or ulceration. - Severe ocular pain. - Stevens‑Johnson syndrome (rare). - Vision loss.

Precautions should be observed when using Dorzolamide eye drops. Pregnancy: consult a healthcare provider; safety not established. Breastfeeding: avoid unless benefits outweigh potential risks. Contact lens wearers: remove lenses before instillation and wait before reinserting. Concurrent ocular surgery: inform the surgeon of Dorzolamide use. Systemic carbonic anhydrase inhibitors: monitor for additive intra‑ocular pressure reduction. Store at room temperature: keep in the original container, protect from light and moisture.

Dorzolamide may interact with other ocular or systemic agents. Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive pressure‑lowering effect may cause hypotony. - Topical beta‑blockers: risk of excessive intra‑ocular pressure reduction. Moderate Interactions (Monitor Closely): - Topical corticosteroids: may increase risk of ocular irritation. - Systemic sulfonamides: potential cross‑reactivity. - Anticholinergic eye drops: may affect tear film stability.